Td Asset Management Inc Orchard Therapeutics PLC Transaction History

Td Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$1.16 - $2.23 $40,726 - $78,293	-35,109 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$4.39 - $9.08 $42,784 - $88,493	9,746 Added 38.43%	35,109 $255,000
Q4 2020 Feb 16, 2021	SELL	$3.86 - $5.07 $124,542 - $163,583	-32,265 Reduced 55.99%	25,363 $110,000
Q3 2020 Nov 10, 2020	SELL	$4.11 - $6.45 $137,841 - $216,320	-33,538 Reduced 36.79%	57,628 $237,000
Q2 2020 Aug 13, 2020	BUY	$5.75 - $11.99 $4,025 - $8,393	700 Added 0.77%	91,166 $547,000
Q1 2020 May 15, 2020	SELL	$5.65 - $15.71 $158,765 - $441,451	-28,100 Reduced 23.7%	90,466 $681,000
Q4 2019 Feb 11, 2020	BUY	$10.15 - $15.58 $116,725 - $179,170	11,500 Added 10.74%	118,566 $1.63 Million
Q3 2019 Nov 07, 2019	BUY	$11.88 - $16.72 $230,472 - $324,368	19,400 Added 22.13%	107,066 $1.27 Million
Q2 2019 Aug 01, 2019	BUY	$13.2 - $20.63 $563,864 - $881,251	42,717 Added 95.03%	87,666 $1.23 Million
Q1 2019 May 08, 2019	BUY	$12.01 - $19.49 $38,432 - $62,367	3,200 Added 7.66%	44,949 $804,000
Q4 2018 Feb 01, 2019	BUY	$12.4 - $18.7 $517,687 - $780,706	41,749 New	41,749 $657,000

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.